Prospective Non-Interventional Study to Investigate the Durable Effectiveness of Risankizumab Using Digital and Remote Evaluation Tools in Moderate to Severe Psoriasis Patients - prIMMa Study
Latest Information Update: 30 Apr 2024
Price :
$35 *
At a glance
- Drugs Risankizumab (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
- Acronyms prIMMa
- Sponsors AbbVie
- 12 Mar 2024 Results (=29) assessing Digital Monitoring of Nocturnal Scratch in Psoriasis Patients Treated with Risankizumab presented at the American Academy of Dermatology annual Meeting 2024
- 02 Jan 2024 Status changed from recruiting to completed.
- 07 May 2021 Status changed from not yet recruiting to recruiting.